Overview
- Apogee announced on Wednesday that it reached a financing agreement with Blackstone Life Sciences worth up to $1.3 billion, combining up to $800 million in staged synthetic royalty funding and access to up to $500 million in senior debt.
- The royalty funding is milestone‑based with an initial $100 million at signing, another $100 million after Phase 3 enrollment, $200 million on positive Phase 3 data, and up to $400 million on FDA approval; royalties are tiered in the low‑to‑mid single digits for 15 years with no royalty above $8 billion in annual sales.
- Apogee also reported Phase 2 APEX Part B results showing the mid‑dose of zumilokibart achieved 65.9% EASI‑75 at Week 16 versus 23.4% for placebo, and the company will advance the mid‑dose into Phase 3 trials planned for the second half of 2026.
- Safety in the mid‑stage trial was generally tolerable with common adverse events including nasopharyngitis, headache, and noninfectious conjunctivitis, and Apogee projects an approximate 10.6% conjunctivitis rate for the planned Phase 3 mid‑dose.
- Investors reacted mixedly to the combined news with some analysts flagging dose‑response questions and the royalty carve‑out’s effect on long‑term revenue and M&A appeal, while others emphasized the strong efficacy signal and non‑dilutive funding that can preserve Apogee’s cash and patient development plans.